DR. DAVID YU-CHIN SHIH, M.D.
Osteopathic Medicine at 23 St, New York, NY
License number
New York 235061
Category
Osteopathic Medicine
Type
Emergency Medicine
Address
Address
37 WEST 23Rd St, New York, NY 10010
Phone
(212) 772-3627
Personal information
See more information about DAVID YU-CHIN SHIH at radaris.comName
Address
Phone
3553 161St St, Flushing, NY 11358
6 Pennypacker Rd, Congers, NY 10920
8115 35Th Ave APT 1D, Jackson Heights, NY 11372
13524 40Th Rd, Flushing, NY 11354
145 4Th Ave APT 18D, New York, NY 10003
Professional information
David Shih
Position:
Operating Supervisor at Consolidated Edison
Location:
Greater New York City Area
Industry:
Utilities
Work:
Consolidated Edison
since Sep 2009
-
Operating Supervisor
Education:
New York University 2012 - 2014
Master of Business Administration (MBA) Columbia University - Fu Foundation School of Engineering and Applied Science 2010 - 2012
M.S., Mechanical Engineering Rensselaer Polytechnic Institute 2005 - 2009
B.S., Mechanical Engineering
Master of Business Administration (MBA) Columbia University - Fu Foundation School of Engineering and Applied Science 2010 - 2012
M.S., Mechanical Engineering Rensselaer Polytechnic Institute 2005 - 2009
B.S., Mechanical Engineering
Entertainment Professional
Location:
Greater New York City Area
Industry:
Entertainment
Skills:
Film, Theatre, Acting, Comedy, Screenwriting, Drama, Film Production, Improvisation, Stage, Creative Direction, Stage Management, Voice Over, Producing, Video, Feature Films, Singing, Dialects, Short Films, Voice Acting, Shakespeare
Dr. David Y Shih, New York NY - MD (Doctor of Medicine)
Specialties:
Emergency Medicine
Address:
1150 3Rd Ave, New York 10065
(212) 933-0007 (Phone)
CITYMD URGENT CARE
315 W 57Th St, New York 10019
(212) 315-2330 (Phone), (646) 682-9304 (Fax)
CITY MD URGENT CARE
336 E 86Th St, New York 10028
(212) 772-3627 (Phone), (212) 772-3628 (Fax)
(212) 933-0007 (Phone)
CITYMD URGENT CARE
315 W 57Th St, New York 10019
(212) 315-2330 (Phone), (646) 682-9304 (Fax)
CITY MD URGENT CARE
336 E 86Th St, New York 10028
(212) 772-3627 (Phone), (212) 772-3628 (Fax)
Certifications:
Emergency Medicine, 2006
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1150 3Rd Ave, New York 10065
CITYMD URGENT CARE
315 W 57Th St, New York 10019
CITY MD URGENT CARE
336 E 86Th St, New York 10028
Huntington Hospital
270 Park Ave, Huntington 11743
CITYMD URGENT CARE
315 W 57Th St, New York 10019
CITY MD URGENT CARE
336 E 86Th St, New York 10028
Huntington Hospital
270 Park Ave, Huntington 11743
Education:
Medical School
Suny Downstate Medical Center
Graduated: 2001
Suny Downstate Medical Center
Graduated: 2001
Owner, Ase Associates
Position:
Owner at ASE Associates
Location:
Greater New York City Area
Industry:
Mechanical or Industrial Engineering
Work:
ASE Associates
since Jul 2001
-
Owner
David Shih
Location:
Greater New York City Area
Industry:
Financial Services
David Shih
Location:
Greater New York City Area
Industry:
Financial Services
Methods For Inhibiting Adipogenesis And For Treating Type 2 Diabetes
US Patent:
2007016, Jul 19, 2007
Filed:
Mar 31, 2004
Appl. No.:
10/551392
Inventors:
Markus Stoffel - New York NY, US
Christian Wolfrum - New York NY, US
David Shih - New York NY, US
Satoru Kuwajima - New York NY, US
Daniel Besser - New York NY, US
Christian Wolfrum - New York NY, US
David Shih - New York NY, US
Satoru Kuwajima - New York NY, US
Daniel Besser - New York NY, US
International Classification:
C12Q 1/68, G01N 33/53, A61K 48/00, A61K 38/17
US Classification:
435006000, 435007100, 514012000, 514044000
Abstract:
The present invention relates to methods for inhibiting adieogenesis and methods for treating obesity, metabolic syndrome and non-insulin dependent diabetes mellitus by administering an agent that increases Foxa-2 or Fxr, or an agent that activates Fxr. The invention is further related to methods for identifying agents that increase Foxa-2 or Fxr, or activate Fxr, and the use of such agents for treatment of obesity, metabolic syndrome and non-insulin dependent diabetes mellitus. Methods of identifying agents that mediate the phosphorylation of the transcription factor Foxa-2 are provided. Such agents are useful in methods of treating Type 2 diabetes.